Page 3 - Targeted Augmentation News Today

BEDFORD, Mass., October 17, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on October 16th, 2023, the company granted a stock option to purchase an aggregate of 32,800 shares of common stock to 1 new employee, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Stoke Therapeutics, Inc. , a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that,...

– Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases –BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating prote...

Stoke Therapeutics, Inc. , a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that...

– Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases – ...

DUBLIN--(BUSINESS WIRE)--Sep 5, 2023--

– Data from multiple ongoing clinical studies of STK-001 show reductions in convulsive seizure frequency and improvements in cognition and behavior in children and adolescents with Dravet syndrome –– Data support the potential for STK-001 to be the first disease-modifying treatment for Dravet syndrome –– New pharmac...

This small-cap biotech might be a hidden gem.

This small-cap biotech might be a hidden gem.

– STK-001: Additional data from patients treated with single and multiple doses along with data from open-label extension studies anticipated in Q1 2024 – – STK-001: Company plans to share...